LOS ANGELES, June 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against UroGen Pharma Ltd. ("UroGen" or "the Company") (NASDAQ: URGN) for violations of §§10(b) and 20(a) of the Securities Exchange...
Hence then, the article about urgn investors have opportunity to lead urogen pharma ltd securities fraud lawsuit with the schall law firm was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm )
Also on site :
- 1969 Beatles Classic Is the Band's Only Song With Over a Billion Streams—And It's Probably Not What You Think
- Jelly Roll Shares First Post Since Filing for Divorce From Bunnie Xo
- After 100 years, the BBC still aspires to be the best of us – and if we take it for granted, we're fools